MOTS-c Reconstitution Calculator

No. MOTS-c is an unapproved peptide sold through the "gray market" alongside BPC-157, CJC-1295, and similar compounds; rigorous human safety data are scarce and there is documented potential for serious harm, including quality-control failures of unregulated products. All human MOTS-c evidence is observational biomarker studies of endogenous circulating levels: no interventional human trial of administered MOTS-c exists (observational).

MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame inside the mitochondrial 12S rRNA gene. It inhibits the folate cycle via AICAR accumulation, activating AMPK, which improves muscle insulin sensitivity and metabolic homeostasis. It functions as an exercise mimetic: rising with exercise and stress (mitohormesis), increasing thermogenesis, and enhancing endurance performance in mice. Additional demonstrated actions include Nrf2 antioxidant signaling, anti-inflammatory effects, and mitochondrial preservation (animal/in-vitro).

No human dosing data exist. Preclinical anchors: 0.5 mg/kg produced maximal cardioprotection (73% infarct size reduction) in ex vivo rat hearts; doses of 0.25–0.7 mg/kg were tested. In vivo mouse studies used 15 mg/kg i.p. twice daily (cancer cachexia), and a rat neurodevelopmental study used 0.5 mg/kg/day i.p. for 26 days. Dose/schedule tables from preclinical metabolic studies are compiled in. Community protocols commonly cite 5–10 mg injected 2–3x/week for 4–8 weeks, but this is not clinically validated (community protocol).

Injectable. Unmodified MOTS-c is highly polar (hydrophobicity index -0.938) with poor membrane permeability; an engineered variant (R13A-MOTS-c) was required to achieve meaningful cellular uptake via the LAT1 transporter. Low bioavailability, poor stability, and short half-life are recognized as the core translational barriers for MDPs. Every efficacy model used i.p., i.v., or perfusion delivery: no oral evidence exists. Subcutaneous injection is the practical default for peptides of this size (community protocol).

Largely no. A rat autism-model study explicitly reports it does not cross the blood-brain barrier (BBB); observed behavioral effects were attributed to peripheral mechanisms. One exception: after traumatic brain injury, peripherally administered MOTS-c was detected in brain tissue, consistent with entry through a disrupted barrier. In an intact barrier, expect peripheral/indirect effects rather than direct CNS action (animal evidence).

No: there are zero human safety data. Endogenous MOTS-c rises in normal pregnancy (not specifically in gestational diabetes). Administered MOTS-c (5 mg/kg) protected placental vascular function and fetal growth in hypoxia-induced intrauterine growth restriction mice via Nrf2, confirming significant placental bioactivity: meaning exogenous peptide could unpredictably alter pregnancy physiology. Avoid during pregnancy and breastfeeding (practitioner consensus).

Endogenous levels track disease state, not longevity. Circulating MOTS-c is lower in type 2 diabetes (meta-analysis SMD -0.89) and in men with T2D, atherosclerosis, or hypertension [11, 13]. Conversely, levels are higher in obesity (SMD +0.51) and in acute coronary syndrome, where elevated MOTS-c predicts major adverse cardiac events [11, 12]. This split (deficient in some states, compensatory in others) means low endogenous MOTS-c does not establish that healthy individuals benefit from supplementation (observational).

Unknown in humans. Animal treatment windows span 2-week daily courses (lung injury) to continuous daily dosing in tumor studies [6, 7], without reported toxicity in those models: but no long-term or human safety data exist. Product purity and labeled content of unregulated purchases cannot be verified. Community practice runs 4–6 week cycles with off periods (community protocol).